Jun 02
Thierry Andre, MD, of @SorbonneTest regarding the outcomes of the Keynote-177 study investigating the use of pembro… https://t.co/kDFozF5pa9

Jun 02
Matthew Galsky @MattGalsky, MD, of @IcahnMountSinai shares the design and outcomes of the Javelin Bladder 100 study… https://t.co/yZ3pRhOiOp

Jun 02
Jorge Cortes @GCC_Cortes, MD, of @GACancerCenter on the evolution of CAR-T cell therapies in hematologic malignanci… https://t.co/GM4S2vb9bd

Jun 02
Salvatore Sienna, MD, of @LaStatale on what is next for Enhertu (trastuzumab deruxtecan) in clinical development… https://t.co/M5eqKkvNUH

Jun 02
Howard Hochster @HH_Oncodr, MD, of @RutgersCancer discusses the outcomes of the Keynote-177 study in metastatic CRC… https://t.co/L9tXQmbWIE

Jun 02
Robert Coleman, MD, FACOG, FACS, of @TheUSONetwork discusses the 2 recent FDA approvals for PARP inhibitors in ovar… https://t.co/oertTlYSSQ

Jun 02
Debu Tripathy, MD: The interim analysis of the very large PALLAS trial testing the addition of 2 years of palbocicl… https://t.co/ThMIREhznz

Jun 01
Alan Venook, MD, of @UCSF discusses the Keynote-177 study investigating MSI High/mismatch repair deficient metastat… https://t.co/6Su3IQK7sN

May 31
Yale Cancer Center Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC #ASCO20 https://t.co/SaOmXmhtiU

May 31
Carfilzomib Does Not Improve Outcomes In Newly Diagnosed Myeloma Compared To Bortezomib #ASCO20 https://t.co/fAh0LUHDFh